Next Article in Journal
Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Next Article in Special Issue
Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives
Previous Article in Journal
In Vitro and In Vivo Biological Activities of Cissus adnata (Roxb.)
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview
Biomedicines 2017, 5(4), 64;

Site-Specific Antibody Conjugation for ADC and Beyond

Protein Engineering, Biologics Research, Sanofi, Framingham, MA 01701, USA
Received: 18 October 2017 / Revised: 4 November 2017 / Accepted: 7 November 2017 / Published: 9 November 2017
(This article belongs to the Special Issue Immunoconjugates)
Full-Text   |   PDF [945 KB, uploaded 10 November 2017]   |  


Antibody-drug conjugates (ADCs) have become a promising class of antitumor agents with four conjugates being approved by regulatory agencies for treating cancer patients. To improve the conventional conjugations that are currently applied to generate these heterogeneous products, various site-specific approaches have been developed. These methods couple cytotoxins or chemotherapeutic drugs to specifically defined sites in antibody molecules including cysteine, glutamine, unnatural amino acids, short peptide tags, and glycans. The ADCs produced showed high homogeneity, increased therapeutic index, and strong antitumor activities in vitro and in vivo. Moreover, there are recent trends in using these next generation technologies beyond the cytotoxin-conjugated ADC. These site-specific conjugations have been applied for the generation of many different immunoconjugates including bispecific Fab or small molecule–antibody conjugates, immunosuppressive antibodies, and antibody–antibiotic conjugates. Thus, it is likely that additional technologies and related site-specific conjugates will emerge in the near future, with various chemicals or small molecular weight proteins in addition to cytotoxin for better treatment of many challenging diseases. View Full-Text
Keywords: site-specific conjugation; specific amino acids; unnatural amino acids; glycans; short peptide tags; ADC; other applications site-specific conjugation; specific amino acids; unnatural amino acids; glycans; short peptide tags; ADC; other applications

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Zhou, Q. Site-Specific Antibody Conjugation for ADC and Beyond. Biomedicines 2017, 5, 64.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top